Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950313 | 0.94 | PARP1 (0.40) | PARP1HTR2AHTR2CTSHRHTR1A | |
| SCHEMBL1057902 | 0.88 | PARP1 (0.52) | PARP1HTR2AHTR2CHTR1AADRA2A | |
| SCHEMBL23258708 | 0.85 | PARP1 (0.40) | PARP1HTR2AHTR2CHTR1AMEN1 | |
| SCHEMBL435085 | 0.76 | PARP1 (0.41) | PARP1TSHRHTR1AADRA2AADRA2B | |
| SCHEMBL30543420 | 0.76 | PARP1 (0.41) | PARP1HTR2CTSHRHTR1AADRA2A | |
| SCHEMBL7517744 | 0.76 | BCL2L1 (0.48) | PARP1HTR2ATSHRHTR1AMEN1 | |
| SCHEMBL15319473 | 0.76 | PARP1 (0.41) | PARP1HTR2CTSHRHTR1AADRA2A | |
| SCHEMBL1812982 | 0.76 | ACHE (0.42) | PARP1HTR2AHTR2CTSHRHTR1A | |
| SCHEMBL20870689 | 0.76 | PARP1 (0.41) | PARP1HTR2AHTR2CTSHRHTR1A | |
| SCHEMBL6584391 | 0.76 | PARP1 (0.44) | PARP1TSHRHTR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| EP-3938340-B1 | HETEROAROMATIC AND HETEROBICYCLIC AROMATIC DERIVATIVES FOR THE TREATMENT OF FERROPTOSIS-RELATED DISORDERS | COLLABORATIVE MEDICINAL DEV LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-3259250-B1 | NOVEL N-ACYL-ARYLSULFONAMIDE DERIVATIVES AS AMINOACYL-TRNA SYNTHETASE INHIBITORS | OXFORD DRUG DESIGN LTD (GB) | 2025-07-02 | — | — | EP | disclosed |
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| EP-3873605-B1 | COMPOUNDS FOR INHIBITION OF ALPHA4BETA7 INTEGRIN | GILEAD SCIENCES INC (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4416143-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | Tango Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118290350-A | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-113631535-B | Heteroaryl and bisheteroaryl derivatives for the treatment of iron death-related disorders | 协同医药发展有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-112969504-B | Compounds for inhibiting alpha 4 beta 7 integrin | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| WO-2003051360-A1 | CIS-IMIDAZOLINES AS MDM2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | WO | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0906912-B1 | Indanol derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-01-08 | — | — | EP | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
| EP-1049662-A1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 2000-11-08 | — | — | EP | disclosed |
| US-6060487-A | Indanol compounds | ADIR ET COMPAGNIE (FR) | 2000-05-09 | — | — | US | disclosed |
| US-5958927-A | PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 1999-09-28 | — | — | US | disclosed |
| WO-1999036393-A1 | INHIBITORS OF α4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO., LTD. (JP) | 1999-07-22 | — | — | WO | disclosed |
| CN-1218051-A | New 2,3-dioxide, indanol compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1999-06-02 | — | — | CN | disclosed |
| EP-0906912-A1 | Indanol derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | PARP1 1677/4885HTR2A 2265/4885HTR2C 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.